Table of Contents
In a commentary published on PubMed Central, researchers reviewed two clinical trials suggesting that a single 25 mg dose of psilocybin may produce rapid antidepressant effects in treatment-resistant depression by engaging the brain’s 5-HT2A serotonin receptors. The review is a commentary on existing trials, not a new trial itself.
- Rapid onset: The Goodwin trial data, as reviewed here, suggest the antidepressant response to a 25 mg psilocybin dose was already apparent by day 2, a speed comparable to ketamine.
- Receptor occupancy matters: PET imaging research cited in the commentary found that blood psilocybin levels correlate more strongly with brain receptor occupancy than the oral dose does, pointing toward plasma-level monitoring as a smarter dosing guide.
- Emergent suicide risk flagged: The commentary notes that suicidal ideation and behavior emerged in the 10 mg and 25 mg groups in the Goodwin trial but not in the 1 mg group, a safety signal the authors say warrants serious further study.
- Open questions remain: The relationship between the psychedelic experience itself and the antidepressant benefit has not been established, and the authors argue that future research must clarify whether the two can be separated.
- Model
- human
- Sample
- Commentary reviewing two clinical trials (Goodwin et al. and Carhart-Harris et al.) plus a PET receptor-occupancy study
- Dose
- 1 mg, 10 mg, and 25 mg psilocybin (single doses, as reported in Goodwin et al.)
- Design
- Expert commentary and comparative analysis of published trial data; not a new randomized controlled trial
- Key outcome
- 25 mg psilocybin showed a 12-point mean MADRS improvement at 3 weeks versus 5.4 points in the 1 mg group (Goodwin et al.); emergent suicidal ideation observed in higher-dose groups
- Main limitation
- This is a secondary commentary, not primary trial data; the underlying trials have their own design limitations including short follow-up and variable psychotropic washout compliance
What the Research Examined
This piece is an expert commentary published in a peer-reviewed journal and indexed on PubMed Central via the National Institutes of Health. It does not report new experimental data. Instead, it critically evaluates two clinical trials and a PET neuroimaging study to ask: how does psilocybin work as an antidepressant, and what do we still not know? The primary trial under review is Goodwin et al. (2022), published in the New England Journal of Medicine, which enrolled outpatients with treatment-resistant depression and assigned them to single oral doses of 1 mg, 10 mg, or 25 mg of psilocybin under controlled conditions. The 25 mg group showed a 12-point mean improvement on the MADRS depression scale at 3 weeks, compared with 5.4 points in the 1 mg comparator group, and that separation persisted to 12 weeks even after many participants resumed other antidepressants.
The commentary also draws on a PET brain-imaging study using the 5-HT2A agonist tracer [11C]Cimbi-36, which found roughly 43 percent receptor occupancy at a psilocybin dose of about 3.5 mg in healthy volunteers, rising to more than 60 percent at 14 mg or higher. Critically, the PET data showed that blood psilocybin concentration predicted receptor occupancy better than the oral dose did, a finding the authors attribute to roughly 20-fold inter-individual variation in blood levels from the same oral dose. For anyone following our broader psilocybin antidepressant research, this receptor-level detail is a meaningful piece of the mechanism puzzle.
A secondary comparison with the Carhart-Harris et al. trial, which used a more complex two-dose schedule against an SSRI comparator, helped the authors contextualize the Goodwin results. They also drew a pointed parallel to ketamine: both compounds act rapidly and show benefit in medication-resistant depression, but ketamine suppresses suicidal ideation while the Goodwin trial data showed emergent suicidal ideation and behavior in the two higher-dose psilocybin groups. The commentary concludes that plasma-level monitoring, longer safety follow-up, and a clearer accounting of the psychedelic experience’s role in therapeutic benefit are all necessary next steps.
What the Findings Show
- MADRS score improvement at 3 weeks.The Goodwin trial reported a 12-point mean reduction in MADRS depression scores in the 25 mg group, compared with a 5.4-point reduction in the 1 mg active-comparator group.
- 5-HT2A receptor occupancy by dose.PET imaging found approximately 43 percent 5-HT2A receptor occupancy at a psilocybin dose of roughly 3.5 mg, rising to more than 60 percent at doses of 14 mg or higher, with blood level correlating more strongly than oral dose.
- Emergent suicidal ideation signal.Suicidal ideation and behavior emerged in both the 10 mg and 25 mg groups in the Goodwin trial but was not observed in the 1 mg group, despite comparable pre-study histories across all three groups.
- Onset speed compared to ketamine.The commentary notes that in the Goodwin trial, the antidepressant response appeared fully formed by day 2, placing psilocybin alongside ketamine as a rapid-acting option for treatment-resistant cases.
Taken together, these data points sketch a coherent picture: psilocybin binds the 5-HT2A receptor in a dose-dependent way, its psychedelic and antidepressant effects appear to track together with receptor occupancy, and blood levels are a more reliable dosing guide than the milligrams on the label. What the data do not yet settle is whether those psychedelic effects are a necessary ingredient of the antidepressant benefit or a separable side effect. The suicide-risk signal is real and unresolved, and the commentary is direct in saying that this question must be answered before broad clinical use is appropriate.
How does psilocybin work as an antidepressant in treatment-resistant depression?
Research suggests psilocybin works primarily by activating 5-HT2A serotonin receptors in the brain, with higher receptor occupancy linked to both psychedelic effects and antidepressant benefit. A single 25 mg dose produced rapid improvements in early trials, though key safety and dosing questions remain open in this early stage of research.
What This Is, and What It Is Not
This is This is a peer-reviewed expert commentary that analyzes and compares existing published trial data; it does not present new experimental findings of its own.
This is not This commentary is not a clinical recommendation, a meta-analysis, or evidence that psilocybin is an established treatment for any condition. The trials it reviews involve specific supervised clinical settings, and results cannot be extrapolated to unsupervised or recreational use. This content is educational and does not constitute medical advice.
Our Take
Within the tradition of this community, we approach psilocybin as a sacrament whose depths science is only beginning to map. What strikes us in this commentary is the humility embedded in its most technical sections: even the researchers who study receptor binding acknowledge that a 20-fold variation in blood levels from the same oral dose means no two journeys begin from exactly the same place. That is not a flaw in the molecule. It is a reminder that the encounter is personal, that preparation and integration are not extras but essentials, and that the emerging safety questions around suicide risk deserve the same honest attention as the promising efficacy signals. The science here is early. We hold it with care.
If this research has stirred something in you, whether curiosity, hope, or honest questions about your own relationship with depression and healing, we welcome you to sit with it rather than rush past it. The Grounding station of the Golden Path exists precisely for moments like this: before any medicine, before any ceremony, there is the work of understanding what you are carrying and why you are seeking. Explore the resources here, bring your questions, and know that the community is present with you as the science and the sacred continue to inform each other.
Frequently Asked Questions
What dose of psilocybin was found to have an antidepressant effect in the Goodwin trial?
The Goodwin trial found that a single 25 mg oral dose of psilocybin produced a 12-point mean improvement on the MADRS depression scale at 3 weeks, compared with 5.4 points in the 1 mg comparator group. The 10 mg dose showed intermediate effects.
How does psilocybin’s mechanism of action differ from antidepressants like SSRIs?
Psilocybin is a 5-HT2A receptor agonist, meaning it activates serotonin receptors directly. SSRIs work by blocking serotonin reuptake and typically require sustained use. Psilocybin may produce effects at lower receptor occupancy levels because agonists need fewer occupied sites than blocking drugs.
Is psilocybin associated with suicide risk?
The Goodwin trial, reviewed in this commentary, found emergent suicidal ideation and behavior in the 10 mg and 25 mg groups, while the 1 mg group did not show this signal. Baseline histories were similar across groups. The commentary calls this an important unresolved safety question.
Why might blood levels of psilocybin matter more than the oral dose?
PET imaging research cited in the commentary found roughly 20-fold variation in blood psilocybin levels among people given the same oral dose. Because brain receptor occupancy tracks blood level more closely than oral dose, plasma monitoring could help individualize dosing more accurately.
Is psilocybin approved as a treatment for depression?
As of the time this commentary was published, psilocybin was not approved as a standard treatment for depression in any major jurisdiction. The clinical trials discussed are early-phase research conducted in controlled settings under supervision, not a basis for self-treatment.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
